Changes in the visual systems of newly diagnosed Parkinson’s disease patients may provide important biomarkers for the early detection and monitoring of the disease, according to a new study published online in the journal Radiology.
“Just as the eye is a window into the body, the visual system is a window into brain disorders,” said lead researcher Alessandro Arrigo, M.D., a resident in ophthalmology at the University Vita-Salute San Raffaele of Milan, Italy.
Parkinson’s disease is a neurodegenerative condition caused by neuronal loss in several brain structures. Parkinson’s disease is characterized by tremors, rigidity or stiffness throughout the body, and impaired balance and coordination.
“Although Parkinson’s disease is primarily considered a motor disorder, several studies have shown non-motor symptoms are common across all stages of the disease,” Dr. Arrigo said. “However, these symptoms are often undiagnosed because patients are unaware of the link to the disease and, as a result, they may be under-treated.”
Non-motor symptoms experienced by patients with Parkinson’s disease include visual alterations such as an inability to perceive colors, a change in visual acuity, and a decrease in blinking which can lead to dry eye. Read more…
Source: Science Daily
Generic medications are substitutes for brand name drugs. They’re typically less expensive, widely available and commonly prescribed. According to the U.S. Food and Drug Administration (FDA), generics account for nearly 90 percent of all prescriptions filled in the United States. And, they can save consumers and hospitals significant amounts in health care costs.
In the treatment of Parkinson’s disease (PD), one of the best-known generics is the immediate release form of carbidopa/levodopa, which substitutes for Sinemet. Recently, rasagiline — the generic of Azilect (an MAO-B inhibitor) — came on the market. With it, questions arose as to what generics really are, how they gain approval and what to consider when taking them.
Generics Are the Same as Brand Name Drugs
Generic drugs are essentially identical to their brand name counterparts. (More about this below.) They:
- are equal in strength (number of milligrams),
- come in the same dosage form (tablet or capsule, for example) and
- are administered via the same route (e.g., oral, inhaler, skin patch).
Generics are prescribed for the same reason as the brand name (i.e., to treat dyskinesia or ease motor symptoms). Modifications that don’t impact the generic’s efficacy or safety are allowed, so drugs may vary in shape, color, flavor or packaging.
FDA Is Responsible for Approving Generics
Companies that wish to make generic medications must submit an application to the FDA that includes data on the drug’s effectiveness and safety. The active ingredient of the generic (the part that provides treatment) must be the same as that in the brand drug, and it must be absorbed by the body at the same rate and to the same extent. (Up to a 20 percent difference in a drug’s absorption is acceptable.) The inactive components (anything other than the active ingredient) must be safe. To demonstrate these properties, clinical trials often are conducted in which volunteers take both brand name and generic formulations (at separate times). Generic manufacturers also supply information on exactly how and where drugs will be produced, and the FDA inspects facilities to ensure generic production will be consistent and reliable.
Generics Can Be Marketed When Patents Expire
Generics can’t be marketed until a brand name drug’s patent and other exclusivities expire. (That’s why there may be a long lag time between generic drug approval and marketing.) These protections grant, among other things, the sole right to the brand name drug maker to sell the medication for a defined period of time so that they can recover some of the drug development costs. (Drug development takes up to a decade and a billion dollars because of the extensive clinical testing involved.) Patent and exclusivity periods may run concurrently but lengths vary depending on a number of factors; patents may last 20 years and exclusivities up to seven. Once these expire, generics can be marketed, typically at a much cheaper price than the brand name because they don’t require lengthy and expensive clinical trials. As multiple generics for the same brand name come on the market, competition can drive costs down even further.
Considerations for Taking Generic Medications in Parkinson’s
If generic medications are available, you may want to take them because of the financial savings. The best way to figure out if generics are an option is to ask your doctor and/or pharmacist. In some situations, your health insurance provider may require that you use the generic option. If, for some reason, you or your doctor prefer the brand name drug, this must be specified on your prescription and you may have a higher out-of-pocket payment. (Learn more about financial and other assistance programs for obtaining medications here.) If you do switch to generic from the brand name:
- monitor for new side effects, which may be the same as those for the brand name, but could potentially differ due to inactive ingredients in the generic, and
- pay attention to any changes in your PD. These would relate to the reason you’re taking the medication. For example, if the medication is to ease Parkinson’s motor symptoms and those seem worse, then perhaps the generic is not ideal for you.
Remember, though, that generics are required to be safe and just as effective as brand name drugs. So, it’s unlikely that they would be less beneficial or cause significant problems. Still, some people don’t respond as well to generics or have new side effects such that they need to take the brand name. As with any medication in your regimen, work with your physician to determine what best suits you and your situation.
Source:: Fox Feed Blog
After a Parkinson’s disease (PD) diagnosis, you may feel isolated from friends and family who aren’t going through the same experience. Meeting with others living with the disease through a support group can help you feel more connected, and introduce you to local resources you may not be familiar with, too.
Support groups are not one size fits all, however, and it may take a few tries before you find the right match. If you’re hesitant to try one out, read these experiences our community shared. Many people who are apprehensive about joining support groups later find them to be an integral part of life with the disease.
Misconception: Support groups are all business.
Reality: Meetings often feature a speaker and an informative discussion, but many have fun at meetings, too. Several commenters shared that as organizers, they also joke around and enjoy the group’s company. Good food and drink help, of course.
By Allyse Falce
On January 12 the U.S. Department of Veterans Affairs (VA) made it easier for certain former service members with Parkinson’s disease (PD) to receive disability benefits. The decision applies to individuals who were exposed to contaminants at Camp Lejeune and later developed PD.
The Foundation’s Unified Parkinson’s Advocacy Council, comprising representatives from state, regional and national PD organizations who gather field-wide input on community policy priorities, sent a letter to the VA last October advocating in support of this decision.
This change will widen access to benefits that can improve quality of life, and it acknowledges evidence linking environmental exposures to Parkinson’s disease.
Source: Fox Feed Blog
Last week, the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for a dyskinesia therapy. Dyskinesia — characterized by uncontrolled, involuntary movements — can be a side effect of the prolonged use of levodopa, the gold standard treatment for Parkinson’s motor symptoms. The results of the FDA review will be announced by August, and if the medication is approved, it would be the first and only available therapy specifically designed to target levodopa-induced dyskinesia.
Developed by Adamas Pharmaceuticals, the drug is an extended-release formulation of amantadine (ADS-5102) that is taken once daily at bedtime. Compared with a shorter-acting form of amantadine already on the market, this new therapy is intended to control symptoms when they are most prevalent (during the day), while not interfering with sleep.
The NDA submitted in October includes a report on safety and efficacy outcomes from three placebo-controlled trials. These trials measured patient response to the drug using the Unified Dyskinesia Rating Scale, a tool supported by The Michael J. Fox Foundation.
Source: Fox Feed Blog
We hope you’ll consider the Parkinson Association of Alabama during the season of giving. It is through the generosity of donors just like you that PAA realizes it’s mission to improve the lives of Parkinson’s patients, caregivers, and loved ones throughout the State.
Click here to donate online or contact Mary T if you’d like to send the gift of a PAA donation to a friend or loved one. For gift donations, we can send the lucky recipient a beautiful card on your behalf to notify them of your gift.
UAB investigators have won a prestigious White House BRAIN Initiative grant to study the potential benefits of new technology coupled with newly discovered biomarkers in deep brain stimulation for Parkinson’s disease.
The University of Alabama at Birmingham has received a BRAIN Initiative grant of $7.3 million over five years from the National Institutes of Health to study new technology that could improve outcomes from deep brain stimulation, an increasingly important treatment for Parkinson’s disease and other movement disorders. [CLICK TO READ MORE]